FENNEC PHARMACEUTICALS INC (FRX.CA) Stock Price & Overview
TSX:FRX • CA31447P1009
Current stock price
The current stock price of FRX.CA is 9.395 CAD. Today FRX.CA is up by 10.53%. In the past month the price decreased by -17.73%. In the past year, price decreased by -4.33%.
FRX.CA Key Statistics
- Market Cap
- 323.94M
- P/E
- N/A
- Fwd P/E
- 15.91
- EPS (TTM)
- -0.37
- Dividend Yield
- N/A
FRX.CA Stock Performance
FRX.CA Stock Chart
FRX.CA Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to FRX.CA. When comparing the yearly performance of all stocks, FRX.CA is a bad performer in the overall market: 86.5% of all stocks are doing better.
FRX.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to FRX.CA. While FRX.CA has a great health rating, there are worries on its profitability.
FRX.CA Earnings
On March 24, 2026 FRX.CA reported an EPS of -0.1 and a revenue of 13.78M. The company missed EPS expectations (-380.11% surprise) and missed revenue expectations (-3.48% surprise).
FRX.CA Forecast & Estimates
13 analysts have analysed FRX.CA and the average price target is 21.34 CAD. This implies a price increase of 127.09% is expected in the next year compared to the current price of 9.395.
For the next year, analysts expect an EPS growth of 259.3% and a revenue growth 64.83% for FRX.CA
FRX.CA Groups
Sector & Classification
FRX.CA Financial Highlights
Over the last trailing twelve months FRX.CA reported a non-GAAP Earnings per Share(EPS) of -0.37. The EPS decreased by -486388759756013500% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -13.81% | ||
| ROE | -27.46% | ||
| Debt/Equity | 0 |
FRX.CA Ownership
FRX.CA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| EPRX | EUPRAXIA PHARMACEUTICALS INC | N/A | 593.929M | ||
| EDT | SPECTRAL MEDICAL INC | N/A | 403.733M | ||
| HBP | HELIX BIOPHARMA CORP | N/A | 152.76M | ||
| COV | COVALON TECHNOLOGIES LTD | 13.25 | 54.688M | ||
| MDNA | MEDICENNA THERAPEUTICS CORP | N/A | 50.052M | ||
| BCT | BRIACELL THERAPEUTICS CORP | N/A | 42.848M | ||
| RVX | RESVERLOGIX CORP | N/A | 34.751M | ||
| MBX | MICROBIX BIOSYSTEMS INC | 3.39 | 33.18M | ||
| MPH | MEDICURE INC | N/A | 14.094M | ||
| HEM | HEMOSTEMIX INC | N/A | 12.691M | ||
| CSCI | COSCIENS BIOPHARMA INC | N/A | 8.65M | ||
| KNE | KANE BIOTECH INC | N/A | 6.365M | ||
| TELO | TELO GENOMICS CORP | N/A | 6.026M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Toronto Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the Canadian exchanges | Find stocks with similar Fundamental rating on the Canadian exchanges | Find the competitors with the best technical ratings on the Canadian exchanges | Find the competitors with the best fundamentals on the Canadian exchanges | Find the competitors with the best valuation on the Canadian exchanges | Find the competitors with the best dividend on the Canadian exchanges | Find the competitors with the best analyst ratings on the Canadian exchanges
About FRX.CA
Company Profile
Fennec Pharmaceuticals, Inc. is a specialty pharmaceutical company. The company is headquartered in Research Triangle Park, North Carolina. The company went IPO on 2001-06-05. The company sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is an approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. The company is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase III clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. The company has established Fennec HEARS, a single source program designed to connect PEDMARK patients.
Company Info
IPO: 2001-06-05
FENNEC PHARMACEUTICALS INC
PO Box 13628, 68 Tw Alexander Dr
RESEARCH TRIANGLE PARK NORTH CAROLINA 27709 US
CEO: Rostislav Raykov
Employees: 36
Phone: 19196364530
FENNEC PHARMACEUTICALS INC / FRX.CA FAQ
What does FENNEC PHARMACEUTICALS INC do?
Fennec Pharmaceuticals, Inc. is a specialty pharmaceutical company. The company is headquartered in Research Triangle Park, North Carolina. The company went IPO on 2001-06-05. The company sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is an approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. The company is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase III clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. The company has established Fennec HEARS, a single source program designed to connect PEDMARK patients.
What is the stock price of FENNEC PHARMACEUTICALS INC today?
The current stock price of FRX.CA is 9.395 CAD. The price increased by 10.53% in the last trading session.
Does FENNEC PHARMACEUTICALS INC pay dividends?
FRX.CA does not pay a dividend.
What is the ChartMill technical and fundamental rating of FRX stock?
FRX.CA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Where is FENNEC PHARMACEUTICALS INC (FRX.CA) stock traded?
FRX.CA stock is listed on the Toronto Stock Exchange exchange.
What is the expected growth for FRX stock?
The Revenue of FENNEC PHARMACEUTICALS INC (FRX.CA) is expected to grow by 64.83% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the ownership details for FRX stock?
You can find the ownership structure of FENNEC PHARMACEUTICALS INC (FRX.CA) on the Ownership tab.